Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Alphs

Showing results (31-40 of 120) with videos related to

Pageof 12
Sort By:
Innovations in Clinical Neuroscience|September 18, 2012
Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalentsJohn J Sheehan, Kristin R Reilly, Dong-Jing Fu, et al.
The Journal of Clinical Psychiatry|November 13, 2012
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophreniaLarry Alphs, William H Olson, Ibrahim Turkoz, et al.
Neuropsychiatric Disease and Treatment|October 5, 2013
Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studiesSrihari Gopal, Yanning Liu, Larry Alphs, et al.
Clinical Schizophrenia & Related Psychoses|June 23, 2011
Training for assessment of negative symptoms of schizophrenia across languages and cultures: comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom factorDavid G Daniel, Larry Alphs, Pilar Cazorla, et al.
The Journal of Nervous and Mental Disease|December 23, 2016
Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective DisorderCynthia A Bossie, Ibrahim Turkoz, Larry Alphs, et al.
The Journal of Clinical Psychiatry|November 7, 2014
Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophreniaLarry Alphs, Lian Mao, Stephen C Rodriguez, et al.
CNS Spectrums|September 16, 2016
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophreniaEdward Kim, Christoph U Correll, Lian Mao, et al.
Journal of Affective Disorders|January 24, 2016
Rapid onset of treatment effects on psychosis, depression, and mania in patients with acute exacerbation of schizoaffective disorder following treatment with oral extended-release paliperidoneDong-Jing Fu, Ibrahim Turkoz, Cynthia A Bossie, et al.
International Journal of Methods in Psychiatric Research|May 4, 2011
Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophreniaLarry Alphs, Robert Morlock, Cheryl Coon, et al.
Psychiatry (Edgmont (Pa. : Township))|December 31, 2010
A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with SchizophreniaWayne Macfadden, Yi-Wen Ma, J Thomas Haskins, et al.
Pageof 12

Showing results (31-40 of 120) with videos related to

Sort By:
Pageof 12
Innovations in Clinical Neuroscience|September 18, 2012
Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalentsJohn J Sheehan, Kristin R Reilly, Dong-Jing Fu, et al.
The Journal of Clinical Psychiatry|November 13, 2012
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophreniaLarry Alphs, William H Olson, Ibrahim Turkoz, et al.
Neuropsychiatric Disease and Treatment|October 5, 2013
Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studiesSrihari Gopal, Yanning Liu, Larry Alphs, et al.
Clinical Schizophrenia & Related Psychoses|June 23, 2011
Training for assessment of negative symptoms of schizophrenia across languages and cultures: comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom factorDavid G Daniel, Larry Alphs, Pilar Cazorla, et al.
The Journal of Nervous and Mental Disease|December 23, 2016
Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective DisorderCynthia A Bossie, Ibrahim Turkoz, Larry Alphs, et al.
The Journal of Clinical Psychiatry|November 7, 2014
Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophreniaLarry Alphs, Lian Mao, Stephen C Rodriguez, et al.
CNS Spectrums|September 16, 2016
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophreniaEdward Kim, Christoph U Correll, Lian Mao, et al.
Journal of Affective Disorders|January 24, 2016
Rapid onset of treatment effects on psychosis, depression, and mania in patients with acute exacerbation of schizoaffective disorder following treatment with oral extended-release paliperidoneDong-Jing Fu, Ibrahim Turkoz, Cynthia A Bossie, et al.
International Journal of Methods in Psychiatric Research|May 4, 2011
Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophreniaLarry Alphs, Robert Morlock, Cheryl Coon, et al.
Psychiatry (Edgmont (Pa. : Township))|December 31, 2010
A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with SchizophreniaWayne Macfadden, Yi-Wen Ma, J Thomas Haskins, et al.
Pageof 12